Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 Signaling.

Tran TH, Utama FE, Sato T, Peck AR, Langenheim JF, Udhane SS, Sun Y, Liu C, Girondo MA, Kovatich AJ, Hooke JA, Shriver CD, Hu H, Palazzo JP, Bibbo M, Auer PW, Flister MJ, Hyslop T, Mitchell EP, Chervoneva I, Rui H.

Clin Cancer Res. 2018 Dec 15;24(24):6355-6366. doi: 10.1158/1078-0432.CCR-17-3280. Epub 2018 Aug 10.

PMID:
30097435
2.

Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment.

Katlinski KV, Gui J, Katlinskaya YV, Ortiz A, Chakraborty R, Bhattacharya S, Carbone CJ, Beiting DP, Girondo MA, Peck AR, Puré E, Chatterji P, Rustgi AK, Diehl JA, Koumenis C, Rui H, Fuchs SY.

Cancer Cell. 2017 Feb 13;31(2):194-207. doi: 10.1016/j.ccell.2017.01.004.

3.

Validation of tumor protein marker quantification by two independent automated immunofluorescence image analysis platforms.

Peck AR, Girondo MA, Liu C, Kovatich AJ, Hooke JA, Shriver CD, Hu H, Mitchell EP, Freydin B, Hyslop T, Chervoneva I, Rui H.

Mod Pathol. 2016 Oct;29(10):1143-54. doi: 10.1038/modpathol.2016.112. Epub 2016 Jun 17.

4.

Jak2-Stat5a/b Signaling Induces Epithelial-to-Mesenchymal Transition and Stem-Like Cell Properties in Prostate Cancer.

Talati PG, Gu L, Ellsworth EM, Girondo MA, Trerotola M, Hoang DT, Leiby B, Dagvadorj A, McCue PA, Lallas CD, Trabulsi EJ, Gomella L, Aplin AE, Languino L, Fatatis A, Rui H, Nevalainen MT.

Am J Pathol. 2015 Sep;185(9):2505-22. doi: 10.1016/j.ajpath.2015.04.026.

5.

Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism.

Goodman CR, Sato T, Peck AR, Girondo MA, Yang N, Liu C, Yanac AF, Kovatich AJ, Hooke JA, Shriver CD, Mitchell EP, Hyslop T, Rui H.

Oncogene. 2016 Mar 17;35(11):1373-85. doi: 10.1038/onc.2015.193. Epub 2015 Jun 22.

6.

The paracrine hormone for the GUCY2C tumor suppressor, guanylin, is universally lost in colorectal cancer.

Wilson C, Lin JE, Li P, Snook AE, Gong J, Sato T, Liu C, Girondo MA, Rui H, Hyslop T, Waldman SA.

Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2328-37. doi: 10.1158/1055-9965.EPI-14-0440. Epub 2014 Oct 10.

7.

Prolactin-Stat5 signaling in breast cancer is potently disrupted by acidosis within the tumor microenvironment.

Yang N, Liu C, Peck AR, Girondo MA, Yanac AF, Tran TH, Utama FE, Tanaka T, Freydin B, Chervoneva I, Hyslop T, Kovatich AJ, Hooke JA, Shriver CD, Rui H.

Breast Cancer Res. 2013;15(5):R73.

8.

Prolactin suppresses a progestin-induced CK5-positive cell population in luminal breast cancer through inhibition of progestin-driven BCL6 expression.

Sato T, Tran TH, Peck AR, Girondo MA, Liu C, Goodman CR, Neilson LM, Freydin B, Chervoneva I, Hyslop T, Kovatich AJ, Hooke JA, Shriver CD, Fuchs SY, Rui H.

Oncogene. 2014 Apr 24;33(17):2215-24. doi: 10.1038/onc.2013.172. Epub 2013 May 27.

9.

Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes.

Peck AR, Witkiewicz AK, Liu C, Klimowicz AC, Stringer GA, Pequignot E, Freydin B, Yang N, Ertel A, Tran TH, Girondo MA, Rosenberg AL, Hooke JA, Kovatich AJ, Shriver CD, Rimm DL, Magliocco AM, Hyslop T, Rui H.

Breast Cancer Res. 2012 Oct 4;14(5):R130. doi: 10.1186/bcr3328.

Supplemental Content

Loading ...
Support Center